<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00748371</url>
  </required_header>
  <id_info>
    <org_study_id>GM15431-JAO1</org_study_id>
    <nct_id>NCT00748371</nct_id>
  </id_info>
  <brief_title>Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration</brief_title>
  <official_title>Loss of Effect of Aspirin on Platelet Aggregation During Chronic Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aspirin has shown to be beneficial to some patients with certain diseases such as coronary&#xD;
      artery disease or stroke. We are investigating how aspirin works on regulating platelets and&#xD;
      thromboxane over time at different doses. We hope to find the best dose of aspirin and/or&#xD;
      other medications to help people who are at risk for heart attack or stroke.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      he purpose of the study is to better understand the mechanism for failure of daily aspirin&#xD;
      administration to prevent cardiovascular events in some at risk individuals. We seek to&#xD;
      describe the effect of chronic aspirin administration at varying doses on platelet&#xD;
      aggregation. This will help to define mechanisms for aspirin failure and to pursue possible&#xD;
      alternative therapies in patients who fail to respond to aspirin therapy.&#xD;
&#xD;
      We hypothesize that (1) inhibition by aspirin (ASA) of ex vivo-induced platelet aggregation&#xD;
      varies in a predictable time and dose dependent manner, (2) thromboxane and prostacyclin&#xD;
      production is inhibited by ASA in a dose-dependent manner and remains relatively constant&#xD;
      over time once maximal inhibition has occurred, and (3) granule secretion by platelets during&#xD;
      induced aggregation is inhibited by aspirin acutely but this effect does not persist during&#xD;
      chronic administration at high doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding issue&#xD;
  </why_stopped>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">February 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of platelet aggregation, serum thromboxane B2 (TxB2) levels, urinary thromboxane metabolite (Tx-M) levels, and urinary prostacyclin metabolite (PGI-M) levels over time and across dose ranges.</measure>
    <time_frame>11 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Platelet Aggregation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA 40mg daily for 8 weeks followed by 3 weeks of observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ASA 1300mg daily for 8 weeks followed by 3 weeks of observation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo: one Avicel (cellulose) capsule by mouth twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening</description>
    <arm_group_label>1</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
    <other_name>ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>1300mg aspirin: one 650-mg capsule by mouth twice daily</description>
    <arm_group_label>2</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
    <other_name>ASA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Placebo: one Avicel (cellulose) capsule by mouth twice daily</description>
    <arm_group_label>3</arm_group_label>
    <other_name>Avicel</other_name>
    <other_name>cellulose</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males&#xD;
&#xD;
          -  Age 18-40 years&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA/NSAID use previous 14 days.&#xD;
&#xD;
          -  Evidence of ASA/NSAID use within previous 14 days at baseline visit based on&#xD;
             investigator interpretation of platelet aggregation and platelet secretion studies.&#xD;
&#xD;
          -  History of chronic NSAID use.&#xD;
&#xD;
          -  Currently taking NSAIDs, corticosteroids, or anticoagulants.&#xD;
&#xD;
          -  History of coronary artery disease, myocardial infarction, coronary artery bypass&#xD;
             grafting, percutaneous angioplasty, diabetes mellitus or stroke.&#xD;
&#xD;
          -  History of gastric,duodenal, or esophageal ulcers or serious gastrointestinal bleed.&#xD;
&#xD;
          -  History of frequent headaches, pain syndrome, or other condition requiring frequent&#xD;
             use of analgesics.&#xD;
&#xD;
          -  History of adverse reaction to ASA.&#xD;
&#xD;
          -  Initial platelet count &lt;100K/µl or &gt;500K/µl.&#xD;
&#xD;
          -  Initial hematocrit &lt;35% or &gt;50%.&#xD;
&#xD;
          -  Weight less than 110 pounds.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John A Oates, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-6602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2008</study_first_posted>
  <last_update_submitted>April 10, 2017</last_update_submitted>
  <last_update_submitted_qc>April 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>John Oates</investigator_full_name>
    <investigator_title>Professor of Medicine and Pharmacology</investigator_title>
  </responsible_party>
  <keyword>platelet aggregation</keyword>
  <keyword>granule secretion</keyword>
  <keyword>thromboxane production</keyword>
  <keyword>prostacyclin production</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

